Repurposing Pirfenidone for Nonalcoholic Steatohepatitis-related Cirrhosis: A Case Series
Open Access
- 24 February 2020
- journal article
- research article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 8 (X), 1-6
- https://doi.org/10.14218/JCTH.2019.00056
Abstract
We repurposed the antifibrotic drug pirfenidone—which is approved for treatment of idiopathic lung fibrosis—in a series of patients with nonalcoholic steatohepatitis-related cirrhosis. Our report demonstrates the observed improvements in necroinflammation and regression of cirrhosis with pirfenidone use for 12-weeks, associated with classical hepatic repair complex features on follow-up liver biopsies. This novel work could help stimulate further randomized trials of pirfenidone in patients with nonalcoholic steatohepatitis-related liver fibrosis or cirrhosis, for whom no recommended drug treatments exists currently.Keywords
This publication has 11 references indexed in Scilit:
- Repurposing drugs to target nonalcoholic steatohepatitisWorld Journal of Gastroenterology, 2019
- Regression of human cirrhosis: an update, 18 years after the pioneering article by Wanless et al.Virchows Archiv A Pathological Anatomy and Histopathology, 2018
- Drug idiosyncrasy due to pirfenidone presenting as acute liver failure: Case report and mini‐review of the literatureHepatology Communications, 2017
- Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitisScientific Reports, 2017
- Prolonged-release pirfenidone is a dual activator for PPARalpha and PPARgamma and improves NASH features induced by high fat/carbohydrate dietJournal of Hepatology, 2017
- Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosisEuropean Respiratory Review, 2015
- Total Body Weight Loss of ≥10 % Is Associated with Improved Hepatic Fibrosis in Patients with Nonalcoholic SteatohepatitisDigestive Diseases and Sciences, 2014
- The multifaceted role of pirfenidone and its novel targetsFibrogenesis & Tissue Repair, 2010
- A pilot study in patients with established advanced liver fibrosis using pirfenidoneGut, 2006
- Pirfenidone in the treatment of primary sclerosing cholangitis.Digestive Diseases and Sciences, 2002